CCWM
VKTX icon

Cassaday & Co Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.8K Buy
2,174
+635
+41% +$20.5K ﹤0.01% 520
2026
Q1 		$50.1K Buy
+1,539
New +$49.5K ﹤0.01% 609

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cassaday & Co Wealth Management's VKTX Position: Q2 2026 in Review

Cassaday & Co Wealth Management increased its Viking Therapeutics (VKTX) stake by 41% in Q2 2026, buying an estimated $20.5K and bringing the position to 2,174 shares worth $84.8K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

Cassaday & Co Wealth Management first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Cassaday & Co Wealth Management held 2,174 shares of Viking Therapeutics worth $84.8K as of Q2 2026.
  • Cassaday & Co Wealth Management bought 635 Viking Therapeutics shares in Q2 2026, an estimated $20.5K.
  • Viking Therapeutics made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #520 holding.
  • Cassaday & Co Wealth Management first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.